Table 3 Patients Characteristics at Baseline
Levodropropizine (LDP) n = 101 | Central Antitussives (CA) n = 60 | No Treatment (NT) n = 80 | p * p < 0,05 LDP. vs CA | |
|---|---|---|---|---|
Age (years), mean (min-max) | 5.9* (0.8-14.8) | 7.3 (1.6-13.3) | 6.3 (0.3-14.0) | NS LDP vs NT NS CA vs NT |
Cough Duration (days), mean (min-max) | 4.6 (2-15) | 5.8 (2-21) | 4.7 (2-17) | NS |
Cough Type (%) | ||||
Productive | 36.6% | 25.0% | 46.3% | NS |
Dry | 50.5% | 63.3% | 40.0% | NS |
Mix | 12.9% | 11.7% | 13.8% | NS |
Cough Intensity (%) | ||||
Mild | 7.9% | 8.3% | 42.5%* | *p < 0.01 NT vs LDP/CA |
Moderate | 58.4% | 53.3% | 51.3% | NS |
Severe | 33.7% | 38.3% | 6.3%* | *p < 0.01 NT vs LDP/CA |
Cough Frequency (%) | ||||
Occasional | 18.8% | 10.0% | 60.0% | NS |
Frequent | 65.3% | 75.0% | 36.3% | NS |
Continuous | 15.8% | 15.0% | 3.8%* | *p < 0.01 NT vs LDP/CA |